Thymoquinone has been shown to inhibit the protein and mRNA expression of eukaryotic elongation factor 2 kinase (eEF-2K) (a critical factor associated with poor patient survival and prognosis) and its downstream signaling molecules, such as Src/Focal adhesion kinase (FAK) and Akt in TNBC, via induction of the tumor suppressor miRNA-603 through suppression of NF-κB [55]. Here, SRC is linked to neoplasm.